Royce & Associates’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-4,809
| Closed | -$205K | – | 970 |
|
|
2021
Q3 | $205K | Sell |
4,809
-4,167
| -46% | -$178K | ﹤0.01% | 970 |
|
|
2021
Q2 | $389K | Sell |
8,976
-1,752
| -16% | -$75.9K | ﹤0.01% | 953 |
|
|
2021
Q1 | $438K | Sell |
10,728
-3,271
| -23% | -$134K | ﹤0.01% | 952 |
|
|
2020
Q4 | $634K | Buy |
13,999
+78
| +0.6% | +$3.53K | 0.01% | 861 |
|
|
2020
Q3 | $493K | Sell |
13,921
-51
| -0.4% | -$1.81K | 0.01% | 865 |
|
|
2020
Q2 | $527K | Buy |
13,972
+143
| +1% | +$5.39K | 0.01% | 852 |
|
|
2020
Q1 | $400K | Sell |
13,829
-1,210
| -8% | -$35K | 0.01% | 857 |
|
|
2019
Q4 | $780K | Buy |
15,039
+31
| +0.2% | +$1.61K | 0.01% | 836 |
|
|
2019
Q3 | $824K | Buy |
15,008
+3,673
| +32% | +$202K | 0.01% | 833 |
|
|
2019
Q2 | $460K | Buy |
11,335
+4,109
| +57% | +$167K | ﹤0.01% | 920 |
|
|
2019
Q1 | $219K | Buy |
7,226
+6,622
| +1,096% | +$201K | ﹤0.01% | 995 |
|
|
2018
Q4 | $20K | Buy |
604
+65
| +12% | +$2.15K | ﹤0.01% | 1104 |
|
|
2018
Q3 | $23K | Buy |
539
+225
| +72% | +$9.6K | ﹤0.01% | 1139 |
|
|
2018
Q2 | $10K | Buy |
314
+166
| +112% | +$5.29K | ﹤0.01% | 1201 |
|
|
2018
Q1 | $7K | Sell |
148
-6
| -4% | -$284 | ﹤0.01% | 1219 |
|
|
2017
Q4 | $8K | Buy |
154
+22
| +17% | +$1.14K | ﹤0.01% | 1206 |
|
|
2017
Q3 | $8K | Buy |
+132
| New | +$8K | ﹤0.01% | 1187 |
|
|
2016
Q2 | – | Sell |
-46,465
| Closed | -$2.08M | – | 1085 |
|
|
2016
Q1 | $2.08M | Sell |
46,465
-12,800
| -22% | -$572K | 0.01% | 815 |
|
|
2015
Q4 | $2.26M | Buy |
+59,265
| New | +$2.26M | 0.01% | 831 |
|
|
2014
Q3 | – | Sell |
-1,300
| Closed | -$60K | – | 1399 |
|
|
2014
Q2 | $60K | Hold |
1,300
| – | – | ﹤0.01% | 1368 |
|
|
2014
Q1 | $53K | Sell |
1,300
-300
| -19% | -$12.2K | ﹤0.01% | 1373 |
|
|
2013
Q4 | $61K | Sell |
1,600
-300
| -16% | -$11.4K | ﹤0.01% | 1380 |
|
|
2013
Q3 | $46K | Hold |
1,900
| – | – | ﹤0.01% | 1404 |
|
|
2013
Q2 | $32K | Buy |
+1,900
| New | +$32K | ﹤0.01% | 1405 |
|